A recent systematic review of active comparator-controlled clinical trials for psoriasis concluded that the newer biologic agents, namely, IL-17 and Il-12/23 inhibitors, are more effective than TNF-a inhibitors in reducing disease severity [52]. This evidence concerns the gene IL17A and psoriasis.